(Press-News.org) Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink – or fail to shrink.
Using special software and MRI scanners, imaging experts at Johns Hopkins developed their new assay, known as a volumetric functional MRI scan, by exploiting the physiological differences in water movement and absorption inside cancer cells that are dying and those that are not.
The studies are believed to be the first to show that the diagnostic imaging procedure buys patients many months to well over a year of life, by figuring out who might benefit from repeat or higher-dose chemotherapy,
The paired scans, which take only minutes to perform, can detect the movement of water molecules inside tumor cells; and software performs the mathematical analysis needed to calculate the imaged tumor cells' so-called apparent diffusion coefficient. Living tumor cells showing a low coefficient, as water absorption in and out of the cells is tightly controlled, and dying cells – the goal of chemotherapy – have a relatively high coefficient, because the tumor cells' membranes have lost the ability to restrict water movement. The software used in the scans was developed at Johns Hopkins and at Siemens Healthcare Diagnostics, which manufactures the scanners.
"Our latest volumetric functional MRI scans could help people with aggressive cancers, and little time to spare on failed treatments, know as quickly as possible if their treatment is working and when they need to consider other treatment options. And without having to wait for months to actually see tumor shrinkage," says study senior investigator and radiologist Ihab Kamel, M.D., Ph.D.
Results from the first of two studies to be published in the same July 1 issue of the journal Radiology show that the high-precision, 3-D images, taken shortly before and one month after a form of chemotherapy called transcatheter arterial chemoembolization, could assess the treatment's impact against a rare and advanced form of liver bile duct cancer, known as cholangiocarcinoma. The study involved 29 men and women aged 29 to 82, all undergoing treatment at The Johns Hopkins Hospital.
Among the key findings in the first study was that 22 people, whose functional MRI scans showed increases in apparent diffusion coefficient scores of over 45 percent, lived at least 10 months longer, while some 17 with coefficient score increases over 60 percent, lived at least 17 months longer.
Kamel, an associate professor at the Johns Hopkins University School of Medicine and its Russell H. Morgan Department of Radiology, says that cholangiocarcinoma is often diagnosed at such an advanced stage that patients only have on average six months to live. "By the time our patients become jaundiced, start turning yellow from bile buildup and seek medical help, it's almost too late," he says. "They have no time to waste on failed treatments."
The second study, also at Johns Hopkins, tested the scans on 26 men and women, ages 37 to 79, with islet cell carcinoma, a well-known pancreatic cancer. Researchers analyzed some 215 tumorous lesions in these people, scanning shortly before and one month after the same initial treatment for their cancer.
Kamel says physicians have more treatment options with islet cell carcinoma and can switch people from chemoembolization to chemotherapy with either drug Sunitinib or Everolimus.
Results in the second study showed that for 78 tumors, which responded well to chemotherapy, functional MRI scans produced apparent diffusion coefficient score increases averaging at least 70 percent, while in the 137 tumors for which treatment was not a success, increases in coefficient measures averaged less than 40 percent. Treatment was considered successful if tumor shrinkage continued for at least six months.
"Our analysis shows how to clearly define and demarcate between patients whose tumors are responding to treatment and those who are not," says Kamel. This is very important, he adds, because in islet cell carcinoma, some patients' cancer symptoms, such as headaches, ulcers, pain and diarrhea, can be masked by the liver's hormone production. The disappearance or absence of symptoms is not a reliable indicator of treatment success.
Larger studies already planned will measure how well the apparent diffusion coefficients for each kind of combination chemotherapy predict survival and how much time remains to switch treatment plans.
In transcatheter arterial chemoembolization, interventional radiologists thread an ultrathin catheter through an abdominal artery directly to the main arteries feeding the liver tumor. Drug-eluting beads are delivered to and released directly inside the tumor to kill it by cutting off its blood supply. The roughly half-hour procedure carries a slight risk of bleeding or damage to the blood vessels, while the toxic drug treatment can permanently damage otherwise healthy liver tissue. Most patients are discharged from the hospital within a day, and many are able to resume physical activity and work.
The Cholangiocarcinoma Foundation estimates that some 2,500 people are newly diagnosed each year with the bile duct cancer, most in the moderate to advanced stages of disease.
Studies have estimated that islet cell carcinomas account for at least 1.3 percent of the 44,000 new cases of pancreatic cancer in the United States each year.
INFORMATION:
Funding support for both studies was provided by Siemens Healthcare, of Princeton, N.J., the manufacturer of the MRI scanners used in the study.
Other Hopkins researchers, besides Kamel, involved in these studies were Vivek Gowdra Halappa, M.D.; Susanne Bonekamp, D.V.M., Ph.D.; Celia Corona-Villalobos; Li, Zhen; Margaret Mensa, B.S.N.; Diane Reyes; John Eng, M.D.; Timothy Pawlik, M.D., M.P.H.; Nikhil Bhagat, M.D.; Hong Lai, Ph.D., M.P.H.; and Jean-Francois Geschwind, M.D.
For additional information, go to:
http://www.hopkinsradiology.org/MRI/Faculty/Kamel
http://radiology.rsna.org/
END
Researchers at the Buck Institute for Research on Aging have corrected the genetic mutation responsible for Huntington's Disease (HD) using a human induced pluripotent stem cell (iPSC) that came from a patient suffering from the incurable, inherited neurodegenerative disorder. Scientists took the diseased iPSCs, made the genetic correction, generated neural stem cells and then transplanted the mutation-free cells into a mouse model of HD where they are generating normal neurons in the area of the brain affected by HD. Results of the research are published in the June ...
This press release is available in German.
An organism's ability to make new antibodies and use them to optimize its own immune defenses is of central importance in the fight against pathogens. In the case of severe infections, the overall relative speed with which an immune response proceeds could mean the difference between life and death. An international team of scientists, among them systems immunologist Prof. Michael Meyer-Hermann of the Helmholtz Centre for Infection Research (HZI) of Braunschweig, Germany, has now found that asymmetric division of antibody-producing ...
Researchers have come up with a device that may enable people who are completely unable to speak or move at all to nevertheless manage unscripted back-and-forth conversation. The key to such silent and still communication is the first real-time, brain-scanning speller, according to the report published online on June 28 in Current Biology, a Cell Press publication.
The new technology builds on groundbreaking earlier uses of fMRI brain scans to assess consciousness in people described as being in an unconscious, vegetative state and to enable them to answer yes and no ...
A new study--which includes the first large-scale comparison of fungi that cause rot decay--suggests that the evolution of a type of fungi known as white rot may have brought an end to a 60-million-year-long period of coal deposition known as the Carboniferous period. Coal deposits that accumulated during the Carboniferous, which ended about 300 million years ago, have historically fueled about 50 percent of U.S. electric power generation.
In addition, the study provides insights about diverse fungal enzymes that might be used in the future to help generate biofuels, ...
For want of a nail, the nursery rhyme goes, a kingdom was lost. A similar, seemingly innocuous change—the evolution of a lineage of mushrooms—may have had a massive impact on the carbon cycle, bringing an end to the 60-million year period during which coal deposits were formed.
Coal generated nearly half of the roughly four trillion kilowatt-hours of electricity consumed in the United States in 2010, according to the U.S. Energy Information Administration. This fuel is actually the fossilized remains of plants that lived from around 360 to 300 million years ago. An international ...
University of Alberta researchers have uncovered physical proof that animals existed 585 million years ago, 30 million years earlier than all previous established records show.
The discovery was made U of A geologists Ernesto Pecoits and Natalie Aubet in Uruguay. They found fossilized tracks of a centimetre long, slug-like animal left behind 585 million years ago in a silty sediment.
Along with other U of A researchers, the team determined that the tracks were made by a primitive animal called a bilaterian, which is distinguished from other non-animal, simple life ...
Both innate and adaptive immune responses play an important role in controlling influenza virus infection, according to a study, published in the Open Access journal PLoS Computational Biology, by researchers from Oakland University, Michigan, and Los Alamos National Laboratory, New Mexico, USA.
Influenza, as a contagious respiratory illness remains a major public health problem worldwide. Seasonal and pandemic influenza results in approximately 3 to 569 million cases of severe illness and approximately 250,000 to 500,000 deaths worldwide. Although most infected subjects ...
300 million years ago, the Earth suddenly interrupted massive production of coal. This fact determined the end of the Carboniferous, a period of the Paleozoic Era that had started 60 million years before, characterized by the successive formation of large carbon beds arising from accumulation and burial of ancient trees growing up in vast marshy forests.
An international scientific team with participation of the Spanish National Research Council (CSIC) has found out that the end of this coal age coincided with the origin of a group of highly specialized fungi. The results, ...
A team of scientists, led by researcher Carles Lalueza-Fox from CSIC (Spanish National Research Council), has recovered - for the first time in history - part of the genome of two individuals living in the Mesolithic Period, 7000 years ago. Remains have been found at La Braña-Arintero site, located at Valdelugueros (León), Spain. The study results, published in the Current Biology magazine, indicate that current Iberian populations don't come from these groups genetically.
The Mesolithic Period, framed between the Paleolithic and Neolithic Periods, is characterized by ...
Astronomer Alain Lecavelier des Etangs (CNRS-UPMC, France) and his team used Hubble to observe the atmosphere of exoplanet HD 189733b [1] during two periods in early 2010 and late 2011, as it was silhouetted against its parent star [2]. While backlit in this way, the planet's atmosphere imprints its chemical signature on the starlight, allowing astronomers to decode what is happening on scales that are too tiny to image directly. The observations were carried out in order to confirm what the team had previously seen once before in a different planetary system: the evaporation ...
